KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) EBIAT (2016 - 2025)

BeOne Medicines (ONC) has disclosed EBIAT for 11 consecutive years, with $243.2 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIAT rose 260.1% to $243.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $463.6 million, a 171.9% increase, with the full-year FY2025 number at $459.4 million, up 171.25% from a year prior.
  • EBIAT was $243.2 million for Q4 2025 at BeOne Medicines, up from $124.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $243.2 million in Q4 2025 to a low of -$590.7 million in Q4 2021.
  • A 5-year average of -$226.2 million and a median of -$299.8 million in 2023 define the central range for EBIAT.
  • Peak YoY movement for EBIAT: crashed 754.48% in 2022, then soared 260.1% in 2025.
  • BeOne Medicines' EBIAT stood at -$590.7 million in 2021, then grew by 24.61% to -$445.3 million in 2022, then rose by 17.47% to -$367.6 million in 2023, then surged by 58.68% to -$151.9 million in 2024, then skyrocketed by 260.1% to $243.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's EBIAT are $243.2 million (Q4 2025), $124.8 million (Q3 2025), and $94.3 million (Q2 2025).